Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06136884 · ClinicalTrials.gov registry record · Phase 1
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
A Phase 1 study of Solid Tumor Malignancies and Brain Metastases From Solid Tumors, sponsored by A2A Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
- 5
- Study locations
NCT06136884 is a Phase 1 study of Solid Tumor Malignancies and Brain Metastases From Solid Tumors that is actively recruiting participants, run by A2A Pharmaceuticals. The registered enrollment target is 86 participants, below the 188-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (54% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT06136884, a Phase 1 study of Solid Tumor Malignancies and Brain Metastases From Solid Tumors, is actively recruiting participants, sponsored by A2A Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Conditions Studied
Interventions
- DRUG AO-252
Study Locations (5)
Texas
- Mary Crowley Cancer Research - Dallas
- The University of Texas M.D. Anderson Cancer Center - Houston
Michigan
- Karmanos Cancer Institute - Detroit
Oklahoma
- Oklahoma Univeristy - Oklahoma City
Virginia
- Next Oncology -Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2023-11-02 |
| Est. Completion | 2028-01-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06136884
The ClinicalTrials.gov registry entry for NCT06136884 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 188-participant average among 11 other Solid Tumor Malignancies trials with a reported enrollment target (54% lower). The listed sponsor is A2A Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumor Malignancies appearing as the primary indexed condition, and to 1 intervention - of which AO-252 is the first listed.
NCT06136884 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Michigan, Oklahoma.
Frequently Asked Questions
What is clinical trial NCT06136884 about?
NCT06136884 is a clinical study titled "A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases". The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
What is the current status of trial NCT06136884?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2023-11-02. Estimated completion is 2028-01-27.
What conditions does trial NCT06136884 study?
This clinical trial studies the following conditions: Solid Tumor Malignancies, Brain Metastases From Solid Tumors.
What interventions are being tested in trial NCT06136884?
The interventions under investigation include: AO-252 (DRUG).
Who is sponsoring clinical trial NCT06136884?
This trial is sponsored by A2A Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06136884 being conducted?
This trial has 5 study locations across Michigan, Oklahoma, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.